Axonyx Inc. has announced the results of an independent study showing that Posiphen increased the ability of transplanted human neuronal stem cells (HNSC) to differentiate into neurons in APP transgenic mice, a model of Alzheimer's disease in humans.
The research was reported by Kiminobu Sugaya, Ph.D., Professor of Molecular Biology, Biomolecular Sciences Center, University of Central Florida, Orlando, Florida at the 9th International Geneva/Springfield Symposium on Advances in Alzheimer's Disease held April 19 - 22, 2006 in Geneva, Switzerland.
Dr. Sugaya's research showed that when APP transgenic mice had been pre-treated with Posiphen, transplanted HNSC start to differentiate into neurons in the brain area where they are needed.
When HNSC were transplanted into the brains of APP transgenic mice in the absence of Posiphen, HNSC did not differentiate into neurons.
Dr. Sugaya attributed this effect to Posiphen's ability to decrease the synthesis of amyloid precursor protein (APP).
Posiphen may support and augment production of the new neurons through the suppression of APP production in the brain. The differentiation of stem cells into functioning neurons is critical to the success of stem cell therapy of AD.
"Although a better understanding of the mechanisms of APP function HNSC biology may be needed," stated Dr. Kiminobu Sugaya.
"Regulation of APP levels by a combination of Posiphen and stem cell treatments could be a promising strategy to treat AD."